Marshall Richard Peter 4

What Happened Marshall Richard Peter, a director of Serina Therapeutics, was granted a derivative award of 15,250 shares (reported as stock options) on June 17, 2026. The award is reported at an acquisition price of $0.00 per share (derivative securities), so there was no cash outlay at grant. This is a grant/award (not a market purchase or sale).

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (check filing timeliness against the 2-business-day rule).
• Amount: 15,250 derivative shares (reported as a grant), price per share: $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to continued service.
• Transaction code: A (award/grant/other acquisition).

Context This was an equity award to a director rather than an open-market purchase or sale. Grants to directors are common as part of compensation and align interests with shareholders; they are not direct indicators of near-term buying or selling. The instruments are described as stock options with specific vesting conditions — they are not reported as having been exercised or sold.